Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.5001
USD
|
-1.75%
|
|
-10.86%
|
-13.82%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
157
|
246.2
|
155
|
20.44
|
5.709
|
Enterprise Value (EV)
1 |
135.7
|
140.7
|
97.74
|
-3.967
|
4.438
|
P/E ratio
|
-6.51
x
|
-6.27
x
|
-6.26
x
|
-0.28
x
|
-2.06
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,331
x
|
190
x
|
9.33
x
|
-42.3
x
|
0.2
x
|
EV / Revenue
|
1,150
x
|
109
x
|
5.88
x
|
8.21
x
|
0.15
x
|
EV / EBITDA
|
-6.32
x
|
-5.36
x
|
-3.96
x
|
0.07
x
|
-6.64
x
|
EV / FCF
|
-10.7
x
|
18.2
x
|
-3.23
x
|
0.18
x
|
-0.22
x
|
FCF Yield
|
-9.38%
|
5.5%
|
-31%
|
565%
|
-460%
|
Price to Book
|
7.49
x
|
3.05
x
|
2.52
x
|
1.96
x
|
0.38
x
|
Nbr of stocks (in thousands)
|
1,479
|
2,869
|
2,920
|
3,371
|
4,965
|
Reference price
2 |
106.2
|
85.80
|
53.10
|
6.063
|
1.150
|
Announcement Date
|
3/8/19
|
3/10/20
|
3/11/21
|
3/25/22
|
3/27/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
9.719
|
0.118
|
1.296
|
16.61
|
-0.483
|
28.83
|
EBITDA
1 |
-11.2
|
-21.46
|
-26.22
|
-24.67
|
-60.23
|
-0.668
|
EBIT
1 |
-11.44
|
-21.82
|
-26.62
|
-25.44
|
-61.35
|
-1.831
|
Operating Margin
|
-117.66%
|
-18,490.68%
|
-2,053.78%
|
-153.11%
|
12,702.07%
|
-6.35%
|
Earnings before Tax (EBT)
1 |
-12.04
|
-22.41
|
-26.3
|
-24.67
|
-64.1
|
-2.373
|
Net income
1 |
-12.04
|
-22.41
|
-26.3
|
-24.67
|
-64.1
|
-2.582
|
Net margin
|
-123.87%
|
-18,994.07%
|
-2,029.55%
|
-148.49%
|
13,271.64%
|
-8.96%
|
EPS
2 |
-35.69
|
-16.32
|
-13.68
|
-8.486
|
-21.70
|
-0.5589
|
Free Cash Flow
1 |
-14.7
|
-12.72
|
7.739
|
-30.26
|
-22.43
|
-20.41
|
FCF margin
|
-151.29%
|
-10,781.25%
|
597.15%
|
-182.12%
|
4,643.12%
|
-70.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/9/18
|
3/8/19
|
3/10/20
|
3/11/21
|
3/25/22
|
3/27/23
|
Fiscal Period: December |
2021 Q1
|
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
---|
Net sales
1 |
0.997
|
0.079
|
-3.677
|
2.118
|
2.565
|
2.471
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-12.16
|
-13.86
|
-23.08
|
-
|
-
|
-
|
Operating Margin
|
-1,219.36%
|
-17,546.84%
|
627.71%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-12.48
|
-14.27
|
-23.53
|
-
|
-
|
-
|
Net income
|
-12.48
|
-14.27
|
-23.53
|
-
|
-
|
-
|
Net margin
|
-1,251.45%
|
-18,062.03%
|
639.95%
|
-
|
-
|
-
|
EPS
2 |
-4.200
|
-4.800
|
-8.100
|
-4.500
|
-2.100
|
-1.660
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/12/21
|
8/12/21
|
11/19/21
|
3/25/22
|
5/16/22
|
8/15/22
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
20.9
|
21.3
|
105
|
57.3
|
24.4
|
1.27
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-14.7
|
-12.7
|
7.74
|
-30.3
|
-22.4
|
-20.4
|
ROE (net income / shareholders' equity)
|
-111%
|
-110%
|
-51.7%
|
-34.7%
|
-176%
|
-19.7%
|
ROA (Net income/ Total Assets)
|
-29.4%
|
-47.2%
|
-23.1%
|
-14.7%
|
-46.4%
|
-2.6%
|
Assets
1 |
40.96
|
47.45
|
113.9
|
167.4
|
138.2
|
99.5
|
Book Value Per Share
2 |
14.50
|
14.20
|
28.10
|
21.10
|
3.100
|
3.000
|
Cash Flow per Share
2 |
19.70
|
17.80
|
16.90
|
11.40
|
9.550
|
1.730
|
Capex
1 |
0.93
|
0.09
|
1.08
|
3.17
|
0.97
|
0.01
|
Capex / Sales
|
9.53%
|
79.66%
|
83.49%
|
19.09%
|
-200.41%
|
0.03%
|
Announcement Date
|
3/9/18
|
3/8/19
|
3/10/20
|
3/11/21
|
3/25/22
|
3/27/23
|
|
1st Jan change
|
Capi.
|
---|
| -13.82% | 4.33M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|